Monopar presents positive uPAR radiopharma dosimetry data at EANM 2024

Monopar Therapeutics

MNPR-101-Lu shows favorable organ safety at high Lu-177 doses using human Zr-89 dosimetry data.
Presentation accepted as 'Top-Rated Oral Presentation' at EANM 2024 in Hamburg, Germany.
Preclinical and clinical data show favorable biodistribution, tumor uptake, and low off-target binding.
MNPR-101-Lu ongoing Phase 1a trial (NCT06617169); MNPR-101-Zr imaging trial (NCT06337084).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.